Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* Meets one of the following disease criteria:~  * Primary acute myelogenous leukemia (AML) induction failure: no complete response (CR )after 2 or more induction attempts~ * Relapsed AML or Secondary AML (from MDS or treatment-related): not in CR after 1 or more cycles of standard induction therapy. For patients \> 60 years of age the 1 cycle of standard chemotherapy is not required if either of the following is met:~* relapse within 6 months of last chemotherapy~* blast count \<30% within 10 days of starting protocol~  * AML relapsed \> 2 months after transplant who do not have the option of donor lymphocyte infusions (e.g. recipients of autologous or umbilical cord blood \[UCB\] transplants)~Patients with prior central nervous system (CNS) involvement are eligible provided that it has been treated and cerebrospinal fluid (CSF) is clear for at least 2 weeks prior to enrollment. CNS therapy (chemotherapy or radiation) should continue as medically indicated during the study treatment.~* Available related HLA-haploidentical donor (3-5 of 6 HLA-A, B and C)~* Karnofsky Performance Status \> 50%~* Adequate organ function defined as:~  * Creatinine: ≤ 2.0 mg/dL~ * Hepatic: Liver function tests (LFT's) \< 5 times upper limit of institutional normal (ULN)~ * Pulmonary Function: oxygen saturation ≥ 90% on room air and pulmonary function \>50% corrected DLCO and FEV1 Testing required only if symptomatic or prior known impairment.~ * Cardiac Function: Ejection fraction (EF) ≥ 40%, no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities~* Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to Natural Killer (NK) cell infusion (excluding preparative regimen pre-medications)~* Women of child bearing potential and men with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy.~* Voluntary written consent~Exclusion Criteria:~* Bi-phenotypic acute leukemia~* Transplant \< 60 days prior to study enrollment~* Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. Women of child bearing potential must have a negative pregnancy test within 14 days of study treatment start~* Active autoimmune disease~* History of severe asthma, presently on chronic medications (a history of mild asthma not requiring therapy is eligible)~* New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that has not been evaluated with bronchoscopy, if feasible. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections). Surgical resection waives any waiting requirements.~* Uncontrolled bacterial or viral infections - chronic asymptomatic viral hepatitis is allowed~* Pleural effusion large enough to be detectable on chest x-ray~* Known hypersensitivity to any of the study agents used~* Received investigational drugs within the 14 days before enrollment~* Known active CNS involvement~Criteria For Initial Donor Selection:~* Related donors (sibling, parent, offspring, parent or offspring of an HLA identical sibling)~* 14-75 years of age~* At least 40 kilogram body weight~* In general good health as determined by the evaluating medical provider~* HLA-haploidentical donor/recipient match (low resolution)~* Not pregnant~* Agree to undergo donor viral screening panel~* Able and willing to undergo apheresis~* Voluntary written consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IL-15 Patients with AML (Type: EXPERIMENTAL): Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML) treated with preparative regimen and Intravenous Recombinant Human IL-15 (rhIL-15)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete